KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.115
-0.005 (-4.10%)
At close: Apr 28, 2026, 4:00 PM EDT
0.115
+0.000 (0.26%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Company Description
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.
The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases.
Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Avi Minkowitz |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781 996 5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Avi Minkowitz | Chief Executive Officer, Chief Financial Officer and Director |
| Mary Reumuth CPA | Treasurer and Secretary |
| Dr. Justin Hanes Ph.D. | Founder and Chair of the Scientific Advisory Board |
| Jill S. Steier | Executive Director of Investor Relations and Corporate Communications |
| Vincent Kosewski | Senior Vice President of Manufacturing and Supply Chain Management |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Josiah Craver CPA | Senior Vice President and Corporate Controller |
| Carl Rennie | Executive Director of Account Management |
| Patrick Bedell | Executive Director of Trade and Alternate Channels |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 17, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 17, 2026 | 144 | Filing |
| Mar 12, 2026 | 144 | Filing |
| Mar 12, 2026 | 144 | Filing |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 17, 2026 | EFFECT | Notice of Effectiveness |
| Feb 17, 2026 | 424B3 | Prospectus |